Alkermes plc is an Irish-headquartered biopharmaceutical firm, established in 1987, focused on the discovery, development, and commercialization of innovative pharmaceutical treatments. These efforts are directed at fulfilling critical unmet medical needs for patients across a range of therapeutic areas, both domestically and internationally. Its current portfolio of marketed products features ARISTADA for schizophrenia; VIVITROL, targeting alcohol dependence and preventing opioid dependence; and several medications for schizophrenia and bipolar I disorder, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA. Furthermore, VUMERITY is available for managing relapsing forms of multiple sclerosis in adults, encompassing clinically isolated syndrome, relapsing-remitting, and active secondary progressive diseases. The company is also actively developing new drug candidates, such as LYBALVI, an oral atypical antipsychotic for adults with schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered fusion protein designed to amplify tumor-killing immune cells while bypassing the activation of immunosuppressive cells. Alkermes maintains key strategic collaboration agreements, primarily with various entities under the Janssen Pharmaceutica umbrella.
